Novo Nordisk aims to double R&D staff
Jesper Brandgaard, CFO of Novo Nordisk |
BEIJING - Diabetes-focused pharmaceutical company Novo Nordisk plans to double its research and development (R&D) capability in China within three to five years, to meet demand in its fastest-growing market and develop tailored solutions for Chinese over the longer term.
Photo